Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in moderate to severe hidradenitis suppurativa
NCT04762277Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of spesolimab in hidradenitis suppurativa (HS), sponsored by Boehringer Ingelheim. Started Apr 2021; status: completed.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04762277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762277.